Effects of the Administration of 25(OH) Vitamin D3 in an Experimental Model of Chronic Kidney Disease in Animals Null for 1-Alpha-Hydroxylase

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Jan 21

PMID 28107527

Citations 3

Authors

Noelia Torremade

Milica Bozic

David Goltzman

Elvira Fernandez

Jose M Valdivielso

Affiliations

Soon will be listed here.

Abstract

The final step in vitamin D activation is catalyzed by 1-alpha-hydroxylase (CYP27B1). Chronic kidney disease (CKD) is characterized by low levels of both 25(OH)D3 and 1,25(OH)2D3 provoking secondary hyperparathyroidism (2HPT). Therefore, treatments with active or native vitamin D compounds are common in CKD to restore 25(OH)D3 levels and also to decrease PTH. This study evaluates the dose of 25(OH)D3 that restores parathyroid hormone (PTH) and calcium levels in a model of CKD in CYP27B1-/- mice. Furthermore, we compare the safety and efficacy of the same dose in CYP27B1+/+ animals. The dose needed to decrease PTH levels in CYP27B1-/- mice with CKD was 50 ng/g. That dose restored blood calcium levels without modifying phosphate levels, and increased the expression of genes responsible for calcium absorption (TRPV5 and calbindinD- 28K in the kidney, TRPV6 and calbindinD-9k in the intestine). The same dose of 25(OH)D3 did not modify PTH in CYP27B1+/+ animals with CKD. Blood calcium remained normal, while phosphate increased significantly. Blood levels of 25(OH)D3 in CYP27B1-/- mice were extremely high compared to those in CYP27B1+/+ animals. CYP27B1+/+ animals with CKD showed increases in TRPV5, TRPV6, calbindinD-28K and calbindinD-9K, which were not further elevated with the treatment. Furthermore, CYP27B1+/+ animals displayed an increase in vascular calcification. We conclude that the dose of 25(OH)D3 effective in decreasing PTH levels in CYP27B1-/- mice with CKD, has a potentially toxic effect in CYP27B1+/+ animals with CKD.

Citing Articles

Methotrexate Chemotherapy Causes Growth Impairments, Vitamin D Deficiency, Bone Loss, and Altered Intestinal Metabolism-Effects of Calcitriol Supplementation.

Su Y, Lee A, Xu X, Hua B, Tapp H, Wen X Cancers (Basel). 2023; 15(17).

PMID: 37686643 PMC: 10486381. DOI: 10.3390/cancers15174367.

Vascular Calcification in Chronic Kidney Disease: An Update and Perspective.

Ren S, Mao N, Yi S, Ma X, Zou J, Tang X Aging Dis. 2022; 13(3):673-697.

PMID: 35656113 PMC: 9116919. DOI: 10.14336/AD.2021.1024.

Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis.

Uenishi K, Tokiwa M, Kato S, Shiraki M Osteoporos Int. 2017; 29(3):723-732.

PMID: 29273827 PMC: 5834567. DOI: 10.1007/s00198-017-4351-2.

References

Carlsson A . The effect of vitamin D on the absorption of inorganic phosphate. Acta Physiol Scand. 1954; 31(4):301-7. DOI: 10.1111/j.1748-1716.1954.tb01144.x. View

Glendenning P, Ratajczak T, Dick I, Prince R . Calcitriol upregulates expression and activity of the 1b isoform of the plasma membrane calcium pump in immortalized distal kidney tubular cells. Arch Biochem Biophys. 2000; 380(1):126-32. DOI: 10.1006/abbi.2000.1908. View

Bozic M, Alvarez A, de Pablo C, Sanchez-Nino M, Ortiz A, Dolcet X . Impaired Vitamin D Signaling in Endothelial Cell Leads to an Enhanced Leukocyte-Endothelium Interplay: Implications for Atherosclerosis Development. PLoS One. 2015; 10(8):e0136863. PMC: 4556440. DOI: 10.1371/journal.pone.0136863. View

Fraser D, KODICEK E . Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature. 1970; 228(5273):764-6. DOI: 10.1038/228764a0. View

Brown A, Dusso A, Slatopolsky E . Vitamin D. Am J Physiol. 1999; 277(2):F157-75. DOI: 10.1152/ajprenal.1999.277.2.F157. View

Tanaka Y, DeLuca H . Stimulation of 24,25-dihydroxyvitamin D3 production by 1,25-dihydroxyvitamin D3. Science. 1974; 183(130):1198-1200. DOI: 10.1126/science.183.4130.1198. View

Slatopolsky E, Cozzolino M, Finch J . Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int. 2002; 62(4):1277-84. DOI: 10.1111/j.1523-1755.2002.kid573.x. View

Glendenning P, Ratajczak T, Prince R, Garamszegi N, Strehler E . The promoter region of the human PMCA1 gene mediates transcriptional downregulation by 1,25-dihydroxyvitamin D(3). Biochem Biophys Res Commun. 2000; 277(3):722-8. DOI: 10.1006/bbrc.2000.3745. View

Goodman W . Recent developments in the management of secondary hyperparathyroidism. Kidney Int. 2001; 59(3):1187-201. DOI: 10.1046/j.1523-1755.2001.0590031187.x. View

10.

Gill R, Christakos S . Identification of sequence elements in mouse calbindin-D28k gene that confer 1,25-dihydroxyvitamin D3- and butyrate-inducible responses. Proc Natl Acad Sci U S A. 1993; 90(7):2984-8. PMC: 46221. DOI: 10.1073/pnas.90.7.2984. View

11.

Craver L, Marco M, Martinez I, Rue M, Borras M, Martin M . Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007; 22(4):1171-6. DOI: 10.1093/ndt/gfl718. View

12.

Deluca H, Prahl J, Plum L . 1,25-Dihydroxyvitamin D is not responsible for toxicity caused by vitamin D or 25-hydroxyvitamin D. Arch Biochem Biophys. 2010; 505(2):226-30. DOI: 10.1016/j.abb.2010.10.012. View

13.

. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42(4 Suppl 3):S1-201. View

14.

Murshed M, Schinke T, McKee M, Karsenty G . Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol. 2004; 165(5):625-30. PMC: 2172384. DOI: 10.1083/jcb.200402046. View

15.

Micheletti R, Fishbein G, Currier J, Singer E, Fishbein M . Calcification of the internal elastic lamina of coronary arteries. Mod Pathol. 2008; 21(8):1019-28. PMC: 7029955. DOI: 10.1038/modpathol.2008.89. View

16.

Qiao J, Doherty T, Fishbein M, Salusky I, Luthringer D, Fitzpatrick L . Calcification of the coronary arteries in the absence of atherosclerotic plaque. Mayo Clin Proc. 2005; 80(6):807-9. DOI: 10.1016/S0025-6196(11)61536-X. View

17.

Stubbs J, Liu S, Tang W, Zhou J, Wang Y, Yao X . Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007; 18(7):2116-24. DOI: 10.1681/ASN.2006121385. View

18.

Peng J, Chen X, Berger U, Vassilev P, Tsukaguchi H, Brown E . Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption. J Biol Chem. 1999; 274(32):22739-46. DOI: 10.1074/jbc.274.32.22739. View

19.

Torremade N, Bozic M, Panizo S, Barrio-Vazquez S, Fernandez-Martin J, Encinas M . Vascular Calcification Induced by Chronic Kidney Disease Is Mediated by an Increase of 1α-Hydroxylase Expression in Vascular Smooth Muscle Cells. J Bone Miner Res. 2016; 31(10):1865-1876. DOI: 10.1002/jbmr.2852. View

20.

Li H, Christakos S . Differential regulation by 1,25-dihydroxyvitamin D3 of calbindin-D9k and calbindin-D28k gene expression in mouse kidney. Endocrinology. 1991; 128(6):2844-52. DOI: 10.1210/endo-128-6-2844. View